Sciverse Solutions, an AI-first Point-of-Care Testing (PoCT) diagnostics company pioneering the future of intelligent, decentralized healthcare, announced a strategic collaboration with Bhat Biotech, a leading Indian biotechnology and molecular diagnostics company. The partnership will focus on co-developing next-generation molecular diagnostic platforms designed to make testing faster, smarter, and more accessible at the point of care.
This collaboration combines Sciverse’s deep expertise in AI, biosensors, microfluidics, and hardware design with Bhat Biotech’s proven capabilities in molecular assay development and manufacturing. Together, both organizations aim to accelerate the development of portable, high-accuracy diagnostic systems capable of delivering lab-quality results in real time — directly at the site of patient care, said the communication note.
“Molecular diagnostics is shaping the future of healthcare — enabling faster, more precise, and accessible disease detection. Our collaboration with Bhat Biotech reflects a shared commitment to redefining how molecular testing can be brought closer to patients, doctors, and healthcare workers everywhere,” said Rahul Singh, managing director of Sciverse Solutions.
Dr. Shama Bhat, founder, Bhat Biotech said, “By integrating Bhat Biotech’s assay chemistry expertise with Sciverse’s device and AI capabilities, we are confident this collaboration will lead to molecular platforms that are more robust, cost-effective, and scalable across global markets.”
Pavan Kumar, managing director, Bhat Biotech said, “This partnership is a natural alignment of strengths. Bhat Biotech’s legacy in molecular innovation and Sciverse’s engineering depth create a strong foundation for building the next era of diagnostic technologies. We look forward to creating solutions that will truly impact healthcare access and quality.” |